{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-10196"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-10196","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration","abstract":"Age-related Macular Degeneration, or AMD will be responsible for the vision impairment of more than 5 million late-aged adults in the next 30 years. Current treatment options include frequent intravitreal injections which report high levels of pain resulting in a low patient compliance. However, there are methods of drug delivery that can decrease the amount of intravitreal injections by sustaining drug release. Polymeric micelles, specifically MPEG-PCL have reported superb biocompatibility and more efficient ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes ranging from 86.76 to 114.51 nm. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto ARPE-19 human retinal pigment epithelial cell line reporting a % viability of more than 88% for all concentrations at time intervals of 24 and 48h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24-72 hour period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD.","abstract_html":"Age-related Macular Degeneration, or AMD will be responsible for the vision impairment of more than 5 million late-aged adults in the next 30 years. Current treatment options include frequent intravitreal injections which report high levels of pain resulting in a low patient compliance. However, there are methods of drug delivery that can decrease the amount of intravitreal injections by sustaining drug release. Polymeric micelles, specifically MPEG-PCL have reported superb biocompatibility and more efficient ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes ranging from 86.76 to 114.51 nm. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto ARPE-19 human retinal pigment epithelial cell line reporting a % viability of more than 88% for all concentrations at time intervals of 24 and 48h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24-72 hour period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD.","abstract_has_math":false,"creators":["Streets, Jarriaun D."],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Graduate School","degree_department":null,"school":null,"contributors":["Vijaykumar Sutariya, Ph.D.","Sheeba Varghese Gupta, M. Pharm, Ph.D.","Pranav Patel, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-03-17T07:00:00Z","date_published":"2020-03-17T07:00:00Z","updated_at":"2026-11-19T08:46:56Z","subjects":["Age-Related Macular Degeneration","Anti-VEGF","MPEG-PCL","Sunitinib","sustained release","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/8999","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/8999","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-10196","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Vijaykumar Sutariya, Ph.D.","Sheeba Varghese Gupta, M. Pharm, Ph.D.","Pranav Patel, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Streets, Jarriaun D."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-03-17T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Graduate School"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Age-Related Macular Degeneration","Anti-VEGF","MPEG-PCL","Sunitinib","sustained release","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/8999"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Age-related Macular Degeneration, or AMD will be responsible for the vision impairment of more than 5 million late-aged adults in the next 30 years. Current treatment options include frequent intravitreal injections which report high levels of pain resulting in a low patient compliance. However, there are methods of drug delivery that can decrease the amount of intravitreal injections by sustaining drug release. Polymeric micelles, specifically MPEG-PCL have reported superb biocompatibility and more efficient ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes ranging from 86.76 to 114.51 nm. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto ARPE-19 human retinal pigment epithelial cell line reporting a % viability of more than 88% for all concentrations at time intervals of 24 and 48h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24-72 hour period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD."]},{"key":"dc:title","label":"Title","values":["Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration"]}]}],"canonical_facts":{"dc:contributor":["Vijaykumar Sutariya, Ph.D.","Sheeba Varghese Gupta, M. Pharm, Ph.D.","Pranav Patel, Ph.D."],"dc:creator":["Streets, Jarriaun D."],"dc:date":["2020-03-17T07:00:00Z"],"dc:description":["Age-related Macular Degeneration, or AMD will be responsible for the vision impairment of more than 5 million late-aged adults in the next 30 years. Current treatment options include frequent intravitreal injections which report high levels of pain resulting in a low patient compliance. However, there are methods of drug delivery that can decrease the amount of intravitreal injections by sustaining drug release. Polymeric micelles, specifically MPEG-PCL have reported superb biocompatibility and more efficient ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes ranging from 86.76 to 114.51 nm. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto ARPE-19 human retinal pigment epithelial cell line reporting a % viability of more than 88% for all concentrations at time intervals of 24 and 48h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24-72 hour period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD."],"dc:identifier":["https://digitalcommons.usf.edu/etd/8999"],"dc:subject":["Age-Related Macular Degeneration","Anti-VEGF","MPEG-PCL","Sunitinib","sustained release","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"],"dc:title":["Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration"],"thesis:degree_discipline":["Graduate School"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:46:56Z"}